Online Data Supplement

- Figure E1 MEDLINE search strategy
- Figure E2 Forest plot of baseline demographic variables (continuous) and outcomes
- Figure E3 Forest plot for 12m FVC (ml) change stratified by baseline FVC
- Figure E4 Forest plot for 3-month FVC change in predicting outcomes in those with a baseline FVC ≥ 80%
- Figure E5 Forest plot for 12m FVC (ml) change stratified by 3m FVC change
- Figure E6 Forest plot for 3-month FVC empirical mortality threshold (5.7%) applied to all studies.
- Figure E7 Forest plot for 3-month FVC empirical disease progression threshold (3%) applied to all studies
- Figure E8 Forest plot for 3-month DLCO threshold change
- Figure E9 Forest plot for 3-month DLco empirical mortality threshold
- Figure E10 Forest plot for 3-month DL_{CO} empirical disease progression threshold
- Figure E11 FVC publication bias
- Figure E12 DLCO publication bias
- Figure E13 6MWD publication bias
- Table E1 Risk of bias assessment
- Table E2 Meta-regression
- Table E3 GRADE assessment
- Table E4 Baseline participant characteristics from studies not included in meta-analysis


- 1. idiopathic pulmonary fibros*.mp.
- 2. pulmonary fibros*.mp.
- 3. Pulmonary Fibrosis/ or Idiopathic Pulmonary Fibrosis/
- 4. cryptogenic fibrosing alveolitis.mp.
- 5. usual interstitial pneumonia*.mp.
- 6. Fibrosing alveolitis.mp.
- 7. Idiopathic Interstitial Pneumonia*.mp.
- 8. Interstitial pneumonia*.mp.
- 9. Idiopathic interstitial lung disease.mp.
- 10. Chronic interstitial pneumonia*.mp.
- 11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
- 12. Forced Vital Capacity.mp. or Vital Capacity/
- 13. FVC.mp.
- 14. Forced Expiratory Volume/ or FEV1.mp.
- 15. forced expiratory volume.mp.
- 16. 6 minute walk.mp.
- 17. Six minute walk.mp.
- 18. Walk Test/
- 19. walk test.mp.
- 20. 6MWT.mp.
- 21. 6MWD.mp.
- 22. Pulmonary diffusing capacity.mp. or Pulmonary Diffusing Capacity/
- 23. Diffusion capacity for carbon monoxide.mp.
- 24. DLCO.mp.
- 25. Transfer factor.mp. or Transfer Factor/
- 26. Gas transfer.mp.
- 27. TLCO.mp.
- 28. KCO.mp.
- 29. PHYSIOLOGY/
- 30. Physiolog*.mp.
- 31. SPIROMETRY/
- 32. spiromet*.mp.
- 33. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
- 34. 11 and 33
- 35. limit 34 to humans

36.. limit 35 to english language

37.. limit 36 to (clinical trial, all or randomized controlled trial)

Figure E1 – MEDLINE search strategy (last search carried out 1st Dec 2020)

А





A: Adjusted hazard ratios (aHR) for overall mortality with 95% confidence intervals shown for each study and pooled estimates

B: Adjusted odds ratios (aOR) for disease progression with 95% confidence intervals shown for each study and pooled estimates

Baseline FVC and Study	12m FVCml change (95% CI)	% Weight	n	Di <1
	·g- (,			
Baseline FVCpp<80%				
ARTEMIS	-63.70 (-162.36, 34.96)	3.73	31	
ASCEND	-268.70 (-305.60, -231.80)	6.98	192	
BUILD1	-139.25 (-221.89, -56.61)	4.45	53	
BUILD3	-129.21 (-180.38, -78.04)	6.17	126	
CAPACITY1	-199.41 (-257.74, -141.08)	5.76	91	
CAPACITY2	-137.68 (-196.23, -79.13)	5.75	106	
IFIGENIA	-116.67 (-222.15, -11.19)	3.47	45	
INPULSIS1	-176.00 (-238.69, -113.31)	5.51	100	
INPULSIS2	-202.58 (-246.96, -158.20)	6.56	118	
TIPAC	-166.94 (-242.20, -91.68)	4.82	49	
TOMORROW	-104.86 (-205.80, -3.92)	3.64	35	
Subgroup (I-squared = 74.4%)	-163.13 (-200.92, -125.33)	56.84		
Baseline FVCpp≥80%				
ARTEMIS	-95.00 (-240.12, 50.12)	2.29	12	
ASCEND	-225.90 (-278.36, -173.44)	6.10	65	
BUILD1	-293.75 (-421.57, -165.93)	2.73	24	
BUILD3	-123.56 (-187.27, -59.85)	5.45	59	
CAPACITY1	-164.69 (-228.99, -100.39)	5.42	70	
CAPACITY2	-163.24 (-209.37, -117.11)	6.46	59	
IFIGENIA	-407.15 (-704.88, -109.42)	0.69	7	
INPULSIS1	-241.51 (-309.77, -173.25)	5.20	65	
INPULSIS2	-204.83 (-287.94, -121.72)	4.43	63	
TIPAC	-323.64 (-531.15, -116.13)	1.31	11	
TOMORROW	-275.00 (-391.82, -158.18)	3.07	20	
Subgroup (I-squared = 49.9%)	-200.78 (-237.14, -164.41)	43.16		
Heterogeneity between groups: p = 0.627				
Overall (I-squared = 64.5%)	-180.92 (-206.86, -154.98)	100.00		

Figure E3 – Forest plot for 12m FVC (ml) change stratified by baseline FVC. Baseline FVC was stratified by a threshold of 80% predicted and FVC (ml) change at 12m was calculated and compared in both groups.




Figure E4 – Forest plot for 3-month FVC change in participants with baseline FVC \ge 80% predicted only. A. Adjusted hazard ratios (aHR) for overall mortality with 95% CI shown per 2.5% decline in FVC. Number of patients who died (n) alongside total patients included (N) in the analysis. B: Adjusted odds ratios (aOR) for disease progression with 95% CI shown per 2.5% decline in FVC over 3 months. Number of progressors (n) alongside total patients included (N) in the analysis. All estimates were adjusted for baseline FVC, age, sex, and smoking status.

		%		Dead
Baseline FVC and Study	12m FVCml change (95% CI)	Weight	n	<12m
3m FVC decline < 2.3%				
ARTEMIS	-41.33 (-140.71, 58.05)	3.97	30	1
ASCEND	-169.94 (-205.62, -134.26)	4.73	121	3
BUILD1	-100.27 (-210.54, 10.00)	3.80	37	0
BUILD3	-2.89 (-45.78, 40.00)	4.67	97	1
CAPACITY1	-120.54 (-174.29, -66.79)	4.56	92	5
CAPACITY2	-59.59 (-112.79, -6.39)	4.57	94	4
IFIGENIA	-3.48 (-139.61, 132.66)	3.41	23	1
INPULSIS1	-104.72 (-162.47, -46.97)	4.52	87	3
INPULSIS2	-144.57 (-211.50, -77.64)	4.41	81	4
MUSIC	-23.85 (-101.99, 54.29)	4.27	26	3
TIPAC	-127.14 (-228.72, -25.56)	3.93	28	9
TOMORROW	-109.44 (-199.93, -18.95)	4.10	36	3
Subgroup (I-squared = 76.1%)	-87.44 (-126.72, -48.16)	50.95		
3m FVC decline > 2.3%				
ARTEMIS -	-125.29 (-249.72, -0.86)	3.59	17	3
ASCEND	-336.15 (-380.70, -291.60)	4.66	136	17
BUILD1	-268.00 (-352.29, -183.71)	4.18	40	2
BUILD3	-253.66 (-314.55, -192.77)	4.49	82	4
CAPACITY1	-269.35 (-335.41, -203.29)	4.42	69	5
CAPACITY2	-262.31 (-316.15, -208.47)	4.56	71	4
FIGENIA	-308.52 (-443.23, -173.81)	3.43	27	2
NPULSIS1	-312.91 (-381.01, -244.81)	4.40	77	5
NPULSIS2	-250.98 (-299.39, -202.57)	4.62	100	8
MUSIC	-382.76 (-491.55, -273.97)	3.83	29	5
TIPAC	-259.67 (-367.57, -151.77)	3.84	30	9
TOMORROW -	-318.13 (-479.88, -156.38)	3.04	16	4
Subgroup (I-squared = 43.7%)	-280.07 (-309.12, -251.03)	49.05		
Heterogeneity between groups: p = 0.000				
Overall (I-squared = 90.8%)	-180.43 (-226.37, -134.48)	100.00		

Figure E5 - Forest plot for 12m FVC (ml) change stratified by 3m FVC change. The median FVC change for all participants was calculated (2.3%) and mean FVC (ml) change at 12m was calculated in participants with a greater than 3m threshold change compared with a change below the threshold.

			Above	Below
		%	threshold	threshold
Variable and Study	aHR (95% CI)	Weight	- dead/total	- dead/total
FVC3m > or < 5.67%				
ARTEMIS	 3.59 (0.55, 28.30) 	3.89	2/33	2/106
ASCEND	8.03 (3.02, 21.30)	11.74	15/86	6/191
BUILD1	2.12 (0.33, 13.70)	4.29	3/27	5/57
BUILD3	 6.55 (1.89, 22.68) 	8.36	9/55	5/148
CAPACITY1 +	1.31 (0.46, 3.67)	10.88	6/42	11/129
CAPACITY2	1.32 (0.45, 3.84)	10.42	5/37	12/136
IFIGENIA	5.16 (0.33, 79.37)	2.14	2/25	1/34
INPULSIS1	 4.73 (1.32, 16.92) 	8.03	6/53	5/141
INPULSIS2	2.20 (0.82, 5.90)	11.60	8/60	10/150
MUSIC	 3.73 (0.98, 14.26) 	7.43	5/23	5/41
TIPAC	1.42 (0.51, 3.99)	10.89	6/24	12/58
TOMORROW	1.40 (0.48, 4.10)	10.32	5/22	13/56
Subgroup (I-squared = 25.2%)	> 2.62 (1.73, 3.96)	100.00		
.015625 1	64			
Decreased mortality	Increased mortality			

Figure E6 – Forest plot for 3-month FVC empirical mortality threshold (5.7%) applied to all studies. An optimum threshold for 3-month relative FVC change in predicting mortality was calculated and pooled. The pooled threshold (5.7%) was applied to all studies to estimate the risk of overall mortality in patients with an FVC decline greater than 5.7% predicted over three months compared with patients who had an FVC decline less than 5.7% predicted.

			Above	Below
		%	threshold	threshold
Variable and Study	aOR (95% CI)	Weight	- Prog/Total	- Prog/Total
FVC3m > or < 3%				
ARTEMIS	 6.14 (1.31, 28.81)	4.55	8/46	5/93
ASCEND	 6.71 (3.89, 11.59)	12.06	94/142	29/135
BUILD1	 2.82 (0.96, 8.25)	7.19	19/40	12/39
BUILD3	 2.65 (1.29, 5.46)	10.24	25/71	18/113
CAPACITY1	 2.00 (1.01, 3.96)	10.66	27/65	27/106
CAPACITY2	 4.32 (2.15, 8.67)	10.51	34/62	23/111
IFIGENIA	 4.50 (1.20, 16.81)	5.64	16/25	9/28
INPULSIS1	 4.01 (2.09, 7.70)	10.97	44/73	27/99
INPULSIS2	 2.03 (1.10, 3.76)	11.33	43/93	34/100
MUSIC	 33.17 (6.57, 167.29)	4.26	24/32	4/31
TIPAC	 1.16 (0.44, 3.10)	7.92	22/35	23/41
TOMORROW	 8.55 (1.87, 39.04)	4.66	13/17	15/42
Subgroup (I-squared = 58.5%)	3.64 (2.47, 5.39)	100.00		

Figure E7 – Forest plot for 3-month FVC empirical disease progression threshold (3%) applied to all studies. An optimum threshold for 3-month relative FVC change in predicting disease progression was calculated and pooled. The pooled threshold (3%) was applied to all studies to estimate the risk of overall disease progression in patients with an FVC decline greater than 3% predicted over three months compared with patients who had an FVC decline less than 3% predicted.




Figure E8 - A: Forest plot of pooled optimal thresholds and 95% confidence intervals for 3-month relative DL_{co} decline in predicting dead or disease progression. Optimal thresholds for 3-month relative DL_{co} change in predicting outcomes were calculated and pooled to create an overall optimal threshold.

B: Forest plot of AUROC for overall optimal threshold (10.5% for mortality and 7.2% for disease progression). The overall optimal threshold was applied to each study to calculate the AUROC, sensitivity and specificity for predicting outcomes.

AUROC, area under receiver operating characteristics curve; Sensitivity and specificity in %.




Figure E9 – Forest plot for 3-month DL_{co} empirical mortality threshold (10.5%) applied to all studies. An optimum threshold for 3-month relative DL_{co} change in predicting mortality was calculated and pooled. The pooled threshold (10.5%) was applied to all studies to estimate the risk of overall mortality in patients with an DL_{co} decline greater than 10.5% predicted over three months compared with patients who had an DL_{co} decline less than 10.5% predicted.




Figure E10 – Forest plot for 3-month DL_{CO} empirical disease progression threshold (7.2%) applied to all studies. An optimum threshold for 3-month relative DL_{CO} change in predicting disease progression was calculated and pooled. The pooled threshold (7.2%) was applied to all studies to estimate the risk of overall disease progression in patients with an DL_{CO} decline greater than 7.2% predicted over three months compared with patients who had an DL_{CO} decline less than 7.2% predicted.




Figure E11 – FVC publication bias. Publication bias assessed using Egger's test where ≥ 10 studies were included.




Figure E12 – DLCO and publication bias. Publication bias assessed using Egger's test where ≥10 studies were included.




Figure E13 – 6MWD and publication bias. Publication bias assessed using Egger's test where ≥10 studies were included.

Study	Study participation	Study attrition	Prognostic factor	Outcome	Confounding
ARTEMIS	Low	High	Moderate	Moderate	Low
ASCEND	Low	Low	Low	Low	Low
BUILD-1	Low	Low	Moderate	Low	Low
BUILD-3	Low	Low	Moderate	Low	Low
CAPACITY	Low	Low	Moderate	Low	Low
IFIGENIA	Low	Low	Moderate	Low	Low
INPULSIS	Low	Low	Moderate	Low	Low
MUSIC	Low	Low	Moderate	Low	Low
TIPAC	Low	Low	Moderate	Low	Low
TOMORROW	Low	Low	Low	Low	Low

Table E1 – Risk of bias assessment. The risk of bias across studies was rated as low, moderate or high risk in five categories using the modified QUIPs tool.

		Baseline FVC				3-month change in FVC			3-month FVC threshold				FVC threshold AUROC					
Variables	Overall r	nortality		ease ession	0	e in FVC 12m	Overall	nortality		ease ession	Overall r (>5.7%	nortality decline)		progression decline)	Overall	nortality	Disease	progression
	R ² (%)	P value	R ² (%)	P value	R ² (%)	P value	R ² (%)	P value	R ² (%)	P value	R ² (%)	P value	R ² (%)	P value	R ² (%)	P value	R ² (%)	P value
FVC vs. non GLI	0.00	0.199	0.00	0.774	17.79	0.191	0.00	0.995	0.00	0.947	8.15	0.163	0.00	0.260	2.84	0.297	6.37	0.175
Concomitant steroid use	0.00	0.413	0.00	0.269	0.00	0.381	2.14	0.343	31.65	0.036	0.00	0.838	16.67	0.119	0.00	0.584	34.74	0.041
Inclusion of severe cases	0.00	0.628	0.00	0.811	22.21	0.157	0.00	0.927	5.99	0.304	0.00	0.497	0.00	0.327	0.00	0.644	0.00	0.411
IPF diagnosis within 5 years	4.94	0.475	0.00	0.811	0.00	0.84	0.00	0.859	0.00	0.476	0.00	0.871	0.00	0.476	0.00	0.622	0.00	0.473
	1																	-
			Baseli	ne DL _{co}			3	-month ch	ange in DL	0		3-month D	L _{co} thresho	old		DL _{co} thres	hold AURC	C
Variables	Overall r	nortality	-	ease ession			Overall I	mortality	_	ease ession		nortality decline)		progression decline)	Overall	mortality	Disease	progression
	R ² (%)	P value	R ² (%)	P value			R ² (%)	P value	R ² (%)	P value	R ² (%)	P value	R ² (%)	P value	R ² (%)	P value	R ² (%)	P value
FVC vs. non GLI	0.00	0.294	0.00	0.498			0.00	0.559	69.57	0.025	100	0.092	0.00	0.770	57.99	0.062	0.00	0.805
Concomitant steroid use	94.17	0.005	99.99	0.077			98.96	0.575	0.00	0.785	100	0.310	0.00	0.810	75.13	0.017	0.00	0.720
Inclusion of severe cases	0.00	0.681	0.00	0.686			0.00	0.927	0.00	0.787	100	0.180	0.00	0.77	100	0.000	0.00	0.805
IPF diagnosis within 5 years	0.00	0.681	0.00	0.811			0.00	0.859	0.00	0.787	N/A	N/A	50.63	0.088	100	0.000	26.22	0.233
			Basolin	e 6MWD			2	month cha	nge in 6MV			_		_		_		_
			Dasellin				3-		lige in olviv	VD								
Variables	Overall r	nortality	-	ease ession			Overall	nortality	-	ease ession								
	R ² (%)	P value	R ² (%)	P value			R ² (%)	P value	R ² (%)	P value								
FVC vs. non GLI	N/A	N/A	N/A	N/A			N/A	N/A	N/A	N/A								
Concomitant steroid use	100	0.006	0.00	0.532			99.99	0.049	99.85	0.479								
Inclusion of severe cases	0.00	0.479	65.17	0.017			N/A	N/A	N/A	N/A								
IPF diagnosis within 5 years	0.00	0.916	65.17	0.017			N/A	N/A	N/A	N/A								

Table E2 - Results of meta-regression for variables assessed separated by study outcomes. Sample sizes for each outcome shown (n). R² and p values from meta-regression shown where applicable. Significant associations (p<0.05) highlighted in red. N/A, not applicable

Outcome	The GRADE domains	Ratings for quality of evidence
Forced Vital Capacity		
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. FVC GLI corrections were applied. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies except one (ARTEMIS: terminated early due to futility)
	Imprecision	Effect sizes in all studies show a similar direction of effect.
Overall mortality (11 studies, 1764 participants)	Inconsistency	No statistical heterogeneity as measured by I ² =0.0%
	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. FVC was measured at baseline in all studies, and overall mortality measured from IPD.
	Publication bias	Publication bias present (p=0.035)
	Certainty of evidence	Moderate certainty of evidence
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. FVC GLI corrections were applied. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies except one (ARTEMIS: terminated early due to futility)
	Imprecision	Effect sizes in most studies show a similar direction of effect.
Disease progression (11 studies, 1526 participants)	Inconsistency	Low statistical heterogeneity as measured by I ² =25.9%
	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. FVC was measured at baseline in all studies, and disease progression definition standardised using IPD.
	Publication bias	No evidence of publication bias
	Certainty of evidence	High certainty of evidence

Change in FVC over 3 months		
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. FVC GLI corrections were applied. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies except one (ARTEMIS: terminated early due to futility)
	Imprecision	Effect sizes in all studies show a similar direction of effect
Overall mortality (12 studies,	Inconsistency	Statistical heterogeneity as measured by I ² =59.4%
1729 participants)	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. FVC was measured at baseline and three months in all included studies, and overall mortality measured from IPD.
	Publication bias	No evidence of publication bias
	Certainty of evidence	Moderate certainty of evidence
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. FVC GLI corrections were applied. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies except one (ARTEMIS: terminated early due to futility)
	Imprecision	Effect sizes in all studies show a similar direction of effect
Disease progression (12	Inconsistency	Substantial heterogeneity (I ² =66.1%)
studies, 1551 participants)	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. FVC was measured at baseline and three months in all included studies and disease progression standardised using IPD.
	Publication bias	Publication bias present (p=0.014)
	Certainty of evidence	Moderate certainty of evidence.

DL _{co}		
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies except one (ARTEMIS: terminated early due to futility)
	Imprecision	Effect sizes in all studies showed a similar direction of effect with varying magnitude
Overall mortality (11 studies; 1734 participants)	Inconsistency	No statistical heterogeneity as measured by I ² =0.0%
	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. DLCO was measured at baseline in all included studies, and overall mortality measured from IPD.
	Publication bias	Publication bias present (p=0.002)
	Certainty of evidence	Moderate certainty of evidence
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies except one (ARTEMIS: terminated early due to futility)
	Imprecision	Effect sizes in all studies showed a similar direction of effect with varying magnitude
	Inconsistency	No statistical heterogeneity as measured by I ² =0.0%
Disease progression (11 studies; 1512 participants)	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. DLCO was measured at baseline in all included studies, and disease progression definition standardised using IPD.
	Publication bias	No publication bias present
	Certainty of evidence	High certainty of evidence

Change in DL _{co} over 3 months		
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies. DL _{co} at 3 months was only available from 6/11 datasets introducing a possible bias
	Imprecision	Effect sizes in all studies show a similar magnitude and direction of effect
Overall mortality (6 studies, 736 participants)	Inconsistency	No statistical heterogeneity as measured by I ² =0.0%
	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. DLCO was measured at baseline and three months in all included studies, and overall mortality measured from IPD.
	Publication bias	No obvious funnel plot asymmetry. Unable to perform Egger's test due to fewer than 10 studies
	Certainty of evidence	Moderate certainty of evidence
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies. DL _{co} at 3 months was only available from 5/11 datasets introducing a possible bias
	Imprecision	Effect sizes in all studies show a similar direction of effect
Disease progression (12 studies, 1551 participants)	Inconsistency	Substantial heterogeneity (I ² =79.2%)
	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. DLCO was measured at baseline and three months in all included studies and disease progression standardised using IPD.
	Publication bias	Funnel plot asymmetry but unable to perform Egger's test due to fewer than 10 studies

	Certainty of evidence	Moderate certainty of evidence.
Baseline 6MWD		
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies except one (ARTEMIS: terminated early due to futility)
	Imprecision	Effect sizes in all studies show a similar magnitude and direction of effect
	Inconsistency	Low heterogeneity (I ² =0.0%)
Overall mortality (6 studies, 828 participants)	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. 6MWD was measured at baseline in all included studies and overall mortality measured from IPD.
	Publication bias	No obvious funnel plot asymmetry. Unable to perform Egger's test due to fewer than 10 studies
	Certainty of evidence	High certainty of evidence.
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies except one (ARTEMIS: terminated early due to futility)
	Imprecision	Effect sizes in all studies show a similar magnitude and direction of effect, though overall estimate is inconclusive.
	Inconsistency	Moderate heterogeneity (I ² =40.4%)
Disease progression (5 studies, 718 participants)	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. 6MWD was measured at baseline and three months in all included studies and disease progression standardised using IPD.
	Publication bias	No obvious funnel plot asymmetry. Unable to perform Egger's test due to fewer than 10 studies

	Certainty of evidence	Low certainty of evidence
Change in 6MWD over 3 months		·
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur. 3-month 6MWD available from 4/6 of datasets.
	Imprecision	Effect sizes in all studies show a similar magnitude and direction of effect
Overall mortality (4 studies, 696 participants)	Inconsistency	No statistical heterogeneity as measured by I ² =0.0%
	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. DL _{co} was measured at baseline and three months in all included studies, and overall mortality measured from IPD.
	Publication bias	Too few studies to assess
	Certainty of evidence	High certainty of evidence
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur. 3-month 6MWD available from 4/6 of datasets.
	Imprecision	Effect sizes in all studies show a similar direction of effect
Disease progression (4 studies, 691 participants)	Inconsistency	High heterogeneity (I ² =79.2%)
	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. DLCO was measured at baseline and three months in all included studies and disease progression standardised using IPD.
	Publication bias	Too few studies to assess

	Certainty of evidence	Moderate certainty of evidence.						
3-month thresholds (FVC)								
Pooled threshold for mortality	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies except one (ARTEMIS: terminated early due to futility)						
	Imprecision	Optimal thresholds showed a similar direction of effect						
	Inconsistency	No heterogeneity detected (I ² = 0%)						
	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. FVC was measured at baseline and three months in all included studies, and overall mortality measured from IPD.						
	Publication bias	Not applicable						
	Certainty of evidence	High certainty of evidence						
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies except one (ARTEMIS: terminated early due to futility)						
	Imprecision	Optimal thresholds showed a similar direction of effect in all studies except one						
Pooled threshold for disease progression	Inconsistency	Low heterogeneity detected (I ² = 31.3%)						
	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. FVC was measured at baseline and three months in all included studies, and disease progression standardised and measured from IPD.						
	Publication bias	Not applicable						

	Certainty of evidence	High certainty of evidence					
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies except one (ARTEMIS: terminated early due to futility)					
	Imprecision	Effect sizes in all studies show a similar direction of effect					
Summary estimates for mortality using 3-month threshold	Inconsistency	Low heterogeneity (I ² =25.2%)					
	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. FVC was measured at baseline and three months in all included studies, and mortality measured from IPD.					
	Publication bias	Not applicable					
	Certainty of evidence	High certainty of evidence					
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow was sufficiently long to enable outcomes to occur in all studies except one (ARTEMIS: terminated early due to futility)					
	Imprecision	Effect sizes in most studies show a similar direction of effect					
	Inconsistency	Substantial heterogeneity (I ² =58.5%)					
Summary estimates for disease progression using 3-month threshold	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. FVC was measured at baseline and three months in all included studies, and disease progression standardised from IPD.					
	Publication bias	Not applicable					
	Certainty of evidence	Moderate certainty of evidence					

3-month thresholds (DL _{co})							
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies. DL _{co} at 3 months was only available from 6/11 datasets introducing a possible bias					
Pooled threshold for mortality	Imprecision	Very wide confidence intervals in most summa estimates, and in pooled estimate					
	Inconsistency	Low heterogeneity (I ² =19.9%)					
	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. DL _{co} was measured at baseline and three months in all included studies, and overall mortality measured from IPD.					
	Publication bias	Not applicable					
	Certainty of evidence	Low certainty of evidence					
	Risk of bias	All studies included well-defined participants diagnosed according to international consensus guidelines. Exposure and outcomes were measured objectively and consistently for all participants. Covariates were adjusted for using IPD. Follow up was sufficiently long to enable outcomes to occur in all studies. DL _{co} at 3 months was only available from 6/11 datasets introducing a possible bias					
Pooled threshold disease progression	Imprecision	Very wide confidence intervals in most summa estimates, and in pooled estimate					
	Inconsistency	No heterogeneity detected (0.0%)					
	Indirectness	No serious indirectness. All patients had IPF according to consensus criteria and were untreated. DL _{co} was measured at baseline and three months in all included studies, and disease progression standardised from IPD.					
	Publication bias	Not applicable					

Certainty of evidence	Low certainty of evidence
-----------------------	---------------------------

Table E3 – GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach to rate the quality of evidence for each of the physiological variables and outcomes

Study and year	Reason for exclusion	Interventional drug	Study phase	Centre	Placebo sample size	Study follow up, months (median)	White ethnicity %	Age (years)	Sex – male (%)	Baseline FVC % predicted	Baseline DL _{CO %} predicted	Baseline 6MWD
Azuma et al, 2005 ¹	Data sharing not permitted by original ethics	Pirfenidone	Phase 2	multi- centre	36	9	-	64.3 (7.6)	94	78.4 (17.2)	57.7 (13.8)	-
Daniels et al, 2010 ²	Data sharing not permitted by original consent	Imatinib	Phase 2	multi- centre	61	22	-	67.8 (52-79) range	64	65.6 (mean only)	39.3 (mean only)	379
Homma et al, 2012 ³	Data sharing not permitted by original ethics	N- acetylcysteine	Phase 3	multi- centre	46	12	-	68.2 (7.7)	76	88.7 (15.5)	64.4 (20.1)	-
King et al, 2009 (INSPIRE)⁴	FDA restrictions on data sharing	Interferon Gamma-1b	Phase 3	multi- centre	275	18	-	65.9 (7.9)	68	73.1 (13.4)	47.3 (9.3)	392.8 (112.9)
Malouf et al, 2011 ⁵	Data sharing not permitted by original ethics	Everolimus	Phase 2	multi- centre	45	36	-	60 (9)	71	69 (20)	42 (14)	451 (118)
Martinez et al, 2014 (PANTHER) ⁶	Data sharing not permitted by original ethics	N- Acetylcysteine /Azathioprine	Phase 3	multi- centre	131	14	96	67.2 (8.2)	75	73.4 (14.3)	46 (12.2)	375 (105)
Noth et al 2012 (ACE-IPF) ⁷	Data sharing not permitted by original ethics	Warfarin	Phase 3	multi- centre	73	12	93	66.7 (7.4)	79	58.7 (16.1)	34.6 (13.4)	280.2 (136.2)
Palmer et al, 2018 ⁸	Offices closed due to Covid-19	BMS-986020	Phase 2	multi- centre	47	6	64	69 (49-85) range	70	69 (48-96) range	45 (12-73) range	-
Parker et al, 2018 ⁹	Data not yet submitted to regulatory authorities	Tralokinumab	Phase 2	multi- centre	59	16	75	67.5 (6.1)	79	70.3 (12.0)	47 (13.8)	391 (112)
Raghu et al, 2004 ¹⁰	FDA restrictions on data sharing	Interferon Gamma-1b	Phase 3	multi- centre	168	13	86	63.4 (8.6)	66	64.1 (11.3)	36.8 (10.6)	-
Raghu et al, 2008 ¹¹	Denied by sponsor	Etanercept	Phase 2	multi- centre	41	12	-	65.1 (7.1)	59	63.0 (12.7)	36.9 (10.8)	396.8 (136.8)
Richeldi et al, 2020 (PRAISE) ¹²	No response from study personnel	Pamrevlumab	Phase 2	multi- centre	53	12	-	68.4 (7.2)	81	73.1 (11.1)	53.8 (12.2)	-
Taniguchi et al, 2009 ¹³	Data sharing not permitted by original ethics	Pirfenidone	Phase 3	multi- centre	104	12	-	64.7 (7.3)	78	79.1 (17.4)	55.2 (18.2)	-

 Table E4 - Baseline participant characteristics from studies where IPD could not be retrieved.

Values for physiological variables reported in mean (standard deviation) unless otherwise stated. 6MWD, six-minute walk distance, DL_{co}, gas transfer for carbon monoxide; FVC, forced vital capacity; MRC, medical research council; -, data not available

References

- Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2005;171(9):1040-7. doi: 10.1164/rccm.200404-571OC [published Online First: 2005/01/25]
- Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. *Am J Respir Crit Care Med* 2010;181(6):604-10. doi: 10.1164/rccm.200906-09640C [published Online First: 2009/12/17]
- 3. Homma S, Azuma A, Taniguchi H, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. *Respirology (Carlton, Vic)* 2012;17(3):467-77. doi: 10.1111/j.1440-1843.2012.02132.x [published Online First: 2012/01/20]
- 4. King TE, Jr., Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. *Lancet* (London, England) 2009;374(9685):222-8. doi: 10.1016/s0140-6736(09)60551-1 [published Online First: 2009/07/03]
- Malouf MA, Hopkins P, Snell G, et al. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. *Respirology (Carlton, Vic)* 2011;16(5):776-83. doi: 10.1111/j.1440-1843.2011.01955.x [published Online First: 2011/03/03]
- 6. Martinez FJ, de Andrade JA, Anstrom KJ, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. *The New England journal of medicine* 2014;370(22):2093-101. doi: 10.1056/NEJMoa1401739 [published Online First: 2014/05/20]
- 7. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;186(1):88-95. doi: 10.1164/rccm.201202-0314OC [published Online First: 2012/05/09]
- Palmer SM, Snyder L, Todd JL, et al. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. *Chest* 2018;154(5):1061-69. doi: 10.1016/j.chest.2018.08.1058 [published Online First: 2018/09/12]
- Parker JM, Glaspole IN, Lancaster LH, et al. A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2018;197(1):94-103. doi: 10.1164/rccm.201704-0784OC [published Online First: 2017/08/09]
- Raghu G, Brown KK, Bradford WZ, et al. A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis. *New England Journal of Medicine* 2004;350(2):125-33. doi: 10.1056/NEJMoa030511
- Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. *Am J Respir Crit Care Med* 2008;178(9):948-55. doi: 10.1164/rccm.200709-14460C [published Online First: 2008/08/02]
- Richeldi L, Fernández Pérez ER, Costabel U, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebocontrolled trial. *The Lancet Respiratory medicine* 2020;8(1):25-33. doi: 10.1016/s2213-2600(19)30262-0 [published Online First: 2019/10/03]
- 13. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. *The European respiratory journal* 2010;35(4):821-9. doi: 10.1183/09031936.00005209 [published Online First: 2009/12/10]